FDA 483 - Intas Pharmaceuticals Limited - July 31, 2017

An FDA inspection of Intas Pharmaceuticals Limited in Ahmedabad, Gujarat, India, revealed a deficiency in sampling procedures for raw materials. Specifically, the firm's method for collecting composite samples from raw material containers was found to be inadequate. This indicates a potential issue with quality control and adherence to established sampling protocols.